| Ongoing | 2/3 | 800 | Europe | AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Revlimid, STA9090, CHR-2797, KPT-330, EMEA/H/C/000717 -PSUV/0074, Revlimid, Revlimid | Cardiff University | Acute myeloid leukemia and high-risk myelodysplastic syndrome | | | | |
2009-014455-68: Study for patients with leukemic cells in their bone marrow. |
|
|
| Ongoing | 2 | 240 | Europe | tosedostat, CHR-2797, Capsule | HOVON Foundation, Haukeland University Hospital, Helse Bergen, HOVON Foundation, Chroma Therapeutics Ltd, Chrma Therapeutics Ltd, Haukeland University Hospital/HOVON | patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 18 years with a confirmed diagnosis of o AML with very poor risk AML, Leukemia, cancer of bone marrow, Diseases [C] - Cancer [C04] | | | | |
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma |
|
|
| Ongoing | 2 | 60 | Europe | CHR-3996, Tosedostat, CHR-3996, CHR-2797, | University of Leeds | Relpsed or refractory multiple myeloma | | | | |